Samsung Biologics Co., Watchlist
Samsung Biologics (207940 KS): Well-Positioned to Leap Forward Without Biogen Deal
184 Views, 20 Jan 2022 23:09
Samsung Biologics Co., (207940 KS) has denied its acquisition talk with Biogen Inc (BIIB US). With its current controversies, Biogen does not seem to be an attractive bet.
- The company is poised for strong growth in 2022, driven by its massive capacity expansion plans and portfolio diversification toward high-growth areas like cell & gene therapies and mRNA business.
- With an increasing order backlog resulting from consistent contract win and expanding customer base, Samsung Biologics has strong revenue visibility.